{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:58:50Z","timestamp":1792195130455,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023262","name":"The Jon Moulton Charity Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["QQ 564477"],"award-info":[{"award-number":["QQ 564477"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010788","name":"International Cancer Imaging Society","doi-asserted-by":"publisher","award":["1:1"],"award-info":[{"award-number":["1:1"]}],"id":[{"id":"10.13039\/100010788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cct.2022.107030","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T14:09:36Z","timestamp":1669471776000},"page":"107030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers"],"prefix":"10.1016","volume":"124","author":[{"given":"Sophie","family":"Merrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nankivell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Quartagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalinie","family":"Joharatnam-Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"O'Carrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Ghorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Badrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Vasudev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.cct.2022.107030_bb0005","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2022.107030_bb0010","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cct.2022.107030_bb0015","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cct.2022.107030_bb0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.annonc.2022.01.003","article-title":"Improving access to immunotherapy in low- and middle-income countries","volume":"33","author":"Patel","year":"2022","journal-title":"Ann Oncol [Internet]"},{"issue":"1","key":"10.1016\/j.cct.2022.107030_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","article-title":"Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors","volume":"8","author":"Bai","year":"2020","journal-title":"Biomark Res."},{"issue":"3","key":"10.1016\/j.cct.2022.107030_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"26","key":"10.1016\/j.cct.2022.107030_bb0035","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.cct.2022.107030_bb0040","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I Study of Single-Agent Anti\u2013Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cct.2022.107030_bb0045","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cpt.656","article-title":"Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis","volume":"101","author":"Liu","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.cct.2022.107030_bb0050","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jcph.1984","article-title":"Pharmacokinetic simulation analysis of less frequent Nivolumab and Pembrolizumab dosing: Pharmacoeconomic rationale for dose Deescalation","volume":"62","author":"Peer","year":"2022","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.cct.2022.107030_bb0055","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1186\/s12885-021-08509-w","article-title":"The DANTE trial protocol: a randomised phase III trial to evaluate the duration of ANti-PD-1 monoclonal antibody treatment in patients with metastatic mElanoma","volume":"21","author":"Coen","year":"2021","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.cct.2022.107030_bb0060","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jjco\/hyaa054","article-title":"A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study)","volume":"50","author":"Nomura","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.cct.2022.107030_bb0065","author":"ECOG-ACRIN Cancer Research Group"},{"issue":"1","key":"10.1016\/j.cct.2022.107030_bb0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12885-021-08018-w","article-title":"Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe stop trial","volume":"21","author":"Mulder","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cct.2022.107030_bb0075","author":"University College, London"},{"issue":"5","key":"10.1016\/j.cct.2022.107030_bb0080","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/1740774518778027","article-title":"Rethinking non-inferiority: a practical trial design for optimising treatment duration","volume":"15","author":"Quartagno","year":"2018","journal-title":"Clin Trials Lond Engl."},{"issue":"6","key":"10.1016\/j.cct.2022.107030_bb0085","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/1740774520944377","article-title":"The DURATIONS randomised trial design: estimation targets, analysis methods and operating characteristics","volume":"17","author":"Quartagno","year":"2020","journal-title":"Clin Trials Lond Engl."},{"issue":"2","key":"10.1016\/j.cct.2022.107030_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.cct.2022.107030_bb0095","series-title":"Introduction to Health Technology Evaluation | NICE Health Technology Evaluations: The Manual | Guidance | NICE [Internet]","year":"2022"},{"issue":"4","key":"10.1016\/j.cct.2022.107030_bb0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40273-014-0247-6","article-title":"An educational review of the statistical issues in analysing utility data for cost-utility analysis","volume":"33","author":"Hunter","year":"2015","journal-title":"PharmacoEconomics."},{"key":"10.1016\/j.cct.2022.107030_bb0105","series-title":"Measuring Mental Health Needs","article-title":"Costing psychiatric interventions","author":"Beecham","year":"2001"},{"key":"10.1016\/j.cct.2022.107030_bb0110","unstructured":"RAMPART Trial [Internet], RAMPART [cited 2022 May 19]. Available from: https:\/\/www.rampart-trial.org\/."},{"issue":"1","key":"10.1016\/j.cct.2022.107030_bb0115","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1186\/s12885-019-6273-1","article-title":"PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma","volume":"19","author":"Buckley","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.cct.2022.107030_bb0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.cct.2022.107030_bb0125","author":"REFINE-Lung (formerly known as CONVOLUTE)"},{"key":"10.1016\/j.cct.2022.107030_bb0130","first-page":"1","article-title":"Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access","volume":"6","author":"Hirsch","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cct.2022.107030_bb0135","author":"Eligibility [Internet]"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422003561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422003561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:38:00Z","timestamp":1778618280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714422003561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":27,"alternative-id":["S1551714422003561"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2022.107030","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2022.107030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107030"}}